REVIVA PHARMACEUTICALS HOLDINGS, INC.

Clinical-stage biopharma developing novel therapies for CNS, respiratory, and metabolic diseases.

RVPH | US

Overview

Corporate Details

ISIN(s):: VGG8708A1167 (+1 more)
LEI:
Country:: United States of America
Address:: 10080 N WOLFE ROAD, 95014 CUPERTINO
Website:: https://revivapharma.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics for diseases with significant unmet medical needs. The company utilizes a chemical genomics-driven technology platform to develop treatments with improved safety and efficacy profiles. Its primary areas of focus include central nervous system (CNS), respiratory, and metabolic diseases. The company's lead drug candidate, brilaroxazine (RP5063), is in clinical development for multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, and psychosis associated with Alzheimer's and Parkinson's diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all REVIVA PHARMACEUTICALS HOLDINGS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for REVIVA PHARMACEUTICALS HOLDINGS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for REVIVA PHARMACEUTICALS HOLDINGS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Equillium, Inc. Clinical-stage biotech creating therapies for severe autoimmune and inflammatory disorders.	United States of America	EQ
Erasca, Inc. Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.	United States of America	ERAS
Ernexa Therapeutics Inc. Developing targeted, off-the-shelf cell therapies for cancer and autoimmune diseases.	United States of America	ERNA
ERYTECH Pharma S.A. Developing phage therapies to combat antibiotic-resistant bacterial infections.	France	ERYP
Esperion Therapeutics, Inc. Develops oral ACLY inhibitors to lower high LDL-C and cardiovascular risk.	United States of America	ESPR
ESSA Pharma Inc. Develops novel small molecule drugs to treat castration-resistant prostate cancer.	United States of America	EPIX
Estrella Immunopharma, Inc. Clinical-stage biopharma developing ARTEMIS® T-cell therapies for cancer & autoimmune disease.	United States of America	ESLA
Eton Pharmaceuticals, Inc. Develops and commercializes innovative treatments for rare pediatric diseases.	United States of America	ETON
EuBiologics Co., Ltd. Develops vaccines for global public health and provides biopharmaceutical CRMO services.	South Korea	206650
EUPRAXIA PHARMACEUTICALS INC. Developing targeted, extended-release therapies for GI and musculoskeletal diseases.	United States of America	EPRX